...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol
【24h】

G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol

机译:结合了纳米结构脂质载体的G5-PEG PAMAM树状聚合物增强了普罗布考的口服生物利用度和降低血浆脂质的作用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

This work aimed to improve the oral bioavailability and plasma lipid-lowering effect of probucol (PB) by constructing a combined drug delivery system (CDDS) composed of nanostructured lipid carrier (NLC) and PEGylated poly(amidoamine) dendrimer (PEG-PAMAM). PEG-PAMAM with dendrimer generations of 5 (G5PEG) or 7 (G7-PEG) were incorporated in PB-NLCs to form PB-CDDSs, PB-NLCs/G5-PEG and PB-NLCs/G7-PEG. The resultant two kinds of PB-CDDSs were characterized by particle size, zeta potential, drug encapsulation efficacy, PB release rates, and physical stability. Formulation effects of NLC and CDDS on the cellular uptake of hydrophobic drug were explored in Caco-2 cells by fluorescent Cy5 dye as a hydrophobic drug model. Furthermore, in vivo pharmacokinetics of the PB-CDDS composed of G5-PEG and PB-NLCs were investigated in a low density lipoprotein receptor knockout (LDLr-/-) mouse model, including plateau plasma PB concentrations after oral administration of multiple doses, and bioavailability after oral administration of a single dose of different PB formulations. In addition, lipid-lowering effect of PB-NLCs/G5-PEG was studied. The results indicate that both G5-PEG and G7-PEG significantly improved aqueous solubility of PB. The two PB-CDDSs exhibited similar particle size (around 150 nm) as PB-NLCs, but slower PB burst release rate, higher total PB release amount, and better particle morphology and storage stability than PB-NLCs. In comparison with traditional NLC, CDDS dramatically enhanced cellular uptake of Cy5 into Caco-2 cells. In vivo results demonstrate that PB-NLCs/G5-PEG had the highest plateau plasma PB concentration and oral bioavailability, and the greatest cholesterollowering effect in comparison with PB suspensions and PB-NLCs. Therefore, G5-PEG incorporating NLC can be exploited as a promising drug delivery system to improve oral bioavailability and lipid-lowering effect of PB. (C) 2015 Elsevier B.V. All rights reserved.
机译:这项工作旨在通过构建由纳米结构脂质载体(NLC)和PEG化聚(酰胺基胺)树状大分子(PEG-PAMAM)组成的联合药物输送系统(CDDS),来提高普罗布考(PB)的口服生物利用度和降低血浆脂质的作用。将具有第5代(G5PEG)或第7代(G7-PEG)树枝状聚合物的PEG-PAMAM掺入PB-NLC中以形成PB-CDDS,PB-NLC / G5-PEG和PB-NLC / G7-PEG。所得的两种PB-CDDSs的特征在于粒径,ζ电位,药物包封功效,PB释放速率和物理稳定性。通过荧光Cy5染料作为疏水性药物模型,探索了NL​​C和CDDS对Caco-2细胞中疏水性药物摄取的影响。此外,在低密度脂蛋白受体敲除(LDLr-/-)小鼠模型中研究了由G5-PEG和PB-NLC组成的PB-CDDS的体内药代动力学,包括多次口服后的高原血浆PB浓度,以及口服单剂不同PB制剂后的生物利用度。此外,研究了PB-NLCs / G5-PEG的降脂作用。结果表明,G5-PEG和G7-PEG均显着改善了PB的水溶性。两种PB-CDDS的粒径(约150 nm)与PB-NLC相似,但与PB-NLC相比,PB爆发释放速率较慢,总PB释放量更高,且颗粒形态和储存稳定性更好。与传统的NLC相比,CDDS显着增强了Cy5对Caco-2细胞的细胞摄取。体内结果表明,与PB悬浮液和PB-NLC相比,PB-NLC / G5-PEG具有最高的血浆血浆PB浓度和口服生物利用度,并且最大的降胆固醇作用。因此,结合了NLC的G5-PEG可以被用作改善PB的口服生物利用度和降脂作用的有前途的药物递送系统。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号